LiquidiaLQDA +6.08%67 EV-to-FCF is 180.15 as of Jun. 30, 2026. GuruFocus rates LQDA with a GF Score™ of 67/100 and a GF Value™ of $218.97 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 558 Drug Manufacturers companies, Liquidia ranks worse than 92.29% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Liquidia's Enterprise Value is $7,052.3 Mil.
Liquidia's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $39.1 Mil. Therefore, Liquidia's EV-to-FCF for today is 180.15.
The historical rank and industry rank for Liquidia's EV-to-FCF or its related term are showing as below:
LQDA'
s EV-to-FCF Range Over the Past 10 Years
Min: -89.42 Med: -7.37 Max: 200.93
Current: 180.15
During the past 10 years, the highest EV-to-FCF of Liquidia was 200.93. The lowest was -89.42. And the median was -7.37.
LQDA's EV-to-FCF is ranked worse than 92.29% of 558
companies
in the Drug Manufacturers industry
Industry Median: 20.045
vs LQDA: 180.15
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Liquidia's share price for today is $79.72.
Liquidia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Liquidia EV-to-FCF Related Terms
Liquidia EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Liquidia's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Liquidia's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liquidia EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liquidia's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Liquidia's EV-to-FCF falls into.
Liquidia's current Enterprise Value is $7,052.3 Mil.
Liquidia's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $39.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liquidia (LQDA) has a EV-to-FCF of 180.15 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Liquidia and its competitors. According to the industry distribution chart, Liquidia ranks #515 out of 558 companies in the Drug Manufacturers industry, placing it in the top 92.3%.
Is Liquidia's EV-to-FCF too high?
Liquidia's current EV-to-FCF is 180.15. The Drug Manufacturers industry median EV-to-FCF is 20.05. Liquidia's value of 180.15 is 798.7% above this industry median. Based on the distribution chart, Liquidia ranks #515 out of 558 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Liquidia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liquidia's EV-to-FCF compare to LNTH and HIMS?
According to the Drug Manufacturers industry distribution chart, Liquidia ranks #515 out of 558 companies for EV-to-FCF. This places Liquidia in the lower half of its industry. The industry median EV-to-FCF is 20.05. Liquidia's value of 180.15 is 798.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.05, based on 558 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liquidia's current EV-to-FCF of 180.15 is 798.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Liquidia and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liquidia's current EV-to-FCF is 180.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liquidia stock overvalued right now?
Based on GuruFocus' analysis, Liquidia (LQDA) is currently considered Possible Value Trap. The stock's GF Value™ is $218.97, compared to a current price of $79.72 — trading 63.6% below its estimated fair value. The current EV-to-FCF is 180.15 and 798.7% above the Drug Manufacturers industry median of 20.05. Liquidia's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Liquidia (LQDA), the current EV-to-FCF is 180.15 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liquidia (LQDA) Overvalued in 2026?
Based on GuruFocus' analysis, Liquidia stock appears to be undervalued.
The current stock price of $79.72 is trading 63.6% below its estimated GF Value™ of $218.97.
GuruFocus considers Liquidia to be Possible Value Trap.
Key valuation signals for LQDA:
EV-to-FCF: 180.15
GF Value™: $218.97 vs. price of $79.72 (63.6% below fair value)
Industry Position: 798.7% above the Drug Manufacturers median (#515 of 558)
No single metric tells the full story. See the LQDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
67GF Score
Get the complete analysis for LQDA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LQDA has been successfully added to your 
